TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00681902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Jet lidocaine compared to jet placebo before needle insertion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Jet saline
Study: NCT04378049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Surgeon will perform a total knee arthroplasty procedure according to local standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted partial knee arthroplasty
Description: Surgeon will perform a robot-assisted unicompartmental or bicompartmental knee arthroplasty procedure
Study: NCT04012294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol Pill
Description: Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant.
Study: NCT02620631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
Study: NCT00688194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: Patients receive aromatase inhibitor therapy according to standard treatment regulations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: Patients receive aromatase inhibitor therapy according to standard treatment regulations.
Study: NCT00688194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Patients receive aromatase inhibitor therapy according to standard treatment regulations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Patients receive aromatase inhibitor therapy according to standard treatment regulations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fulvestrant
Description: Given intramuscularly
Study: NCT05011955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness, compassion and intercare based Intervention
Description: The mindfulness based intervention was a short version of the Mindfulness based intercare program (IBAP). The intervention consists of four synchronic group sessions via ZOOM of one hour each, one peer week and home practice. A total of four groups were conducted of 15 students each.~The IBAP program was inspired by first and second generation mindfulness based interventions, such as Mindfulness based cognitive training, Self-Compassion and Cognitive based Compassion training. Also compassionate communication, conservation of resource theory and habits theory.~Each module consists in meditation practices, inquiry and self or group reflections on different topics such as mindfulness, automatic pilot, mind wandering , acceptance, gratitude and compassion, care resources and intercare.
Study: NCT00688194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fulvestrant
Description: Given intramuscularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fulvestrant
Description: Given intramuscularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fulvestrant
Description: Given intramuscularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib ditosylate
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib ditosylate
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: Patients receive aromatase inhibitor therapy according to standard treatment regulations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: Patients receive aromatase inhibitor therapy according to standard treatment regulations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03277651

Intervention type: DIAGNOSTIC_TEST
Intervention: hemodynamics tests
Description: Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: hemodynamics tests
Description: Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound
Study: NCT01594489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline
Description: * 200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration~* Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydration plus N-acetylcisteine
Description: * Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~* N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI
Study: NCT05661838

Intervention type: PROCEDURE
Intervention: transfusion
Description: transfusion

Intervention type: PROCEDURE
Intervention: transfusion
Description: transfusion
Study: NCT03700866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional splinting time
Description: Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional splinting time
Description: Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
Study: NCT01176864

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-balloon enteroscopy
Description: Double-balloon enteroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-balloon enteroscopy
Description: Single-balloon enteroscopy
Study: NCT01021293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix™
Description: 3 doses, intramuscular administration

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Poliovirus vaccine
Description: 3 doses, oral administration
Study: NCT01134328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-150 Combo
Description: 1 drop in each eye for up to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC-150A 0.1%
Description: 1 drop in each eye once per day for up to 14 days
Study: NCT04165187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Home exercise program will consist of joint range of motion, stretching, strengthening and proprioceptive exercises for lower extremity.
Study: NCT00006046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody hu3S193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody hu3S193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody hu3S193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody hu3S193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody hu3S193
Study: NCT03176472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ricolinostat
Description: 120 mg per dose in 12 mL liquid formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 mL liquid formulation placebo
Study: NCT03584191

Intervention type: OTHER
Intervention: No treatment given
Description: Completion of a survey

Intervention type: OTHER
Intervention: No treatment given
Description: Completion of a survey
Study: NCT00906139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol dose: 0.5 mg/kg up to 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam dose: 0.1 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl dose: 0.05 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl dose: 0.05 mg
Study: NCT02435290

Intervention type: BEHAVIORAL
Intervention: determine the incidence , type , and severity of prescribing errors in the oncology department
Description: patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~.
Study: NCT05011955

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational based intervention
Description: Four week, one hour peer week, online group intervention plus home work base on psychoeducation about stress, anxiety, selfcare and effective communication. Plus general curricular intervention. Delivered by psychologist.

Intervention type: OTHER
Group type: OTHER
Intervention: General curricular intervention
Description: All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General curricular intervention
Description: All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General curricular intervention
Description: All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams.
Study: NCT04230434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Plan Intervention
Description: The SPI has 6 key steps: (1) identify personalized warning signs for an impending suicide crisis; (2) determine internal coping strategies that distract from suicidal thoughts and urges; (3) identify family and friends who are able to distract from suicidal thoughts and urges and social places that provide the opportunity for interaction; (4) identify individuals who can help provide support during a suicidal crisis; (5) list mental health professionals and urgent care services to contact during a suicidal crisis; and (6) lethal means counseling for making the environment safer (Stanley \& Brown, 2012)
Study: NCT01728324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127-placebo: 8-week treatment
Description: 8 weeks of placebo treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin: 24-week treatment
Description: 24 weeks of active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127: 24-week treatment
Description: 24 weeks of active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir: 24-week treatment
Description: 24 weeks of active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir: 24-week treatment
Description: 24 weeks of active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin-placebo: 8-week treatment
Description: 8 weeks of placebo treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127: 24-week treatment
Description: 24 weeks of active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir-placebo: 8-week treatment
Description: 8 weeks of placebo treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir: 16-week treatment
Description: 16 weeks of active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin: 16-week treatment
Description: 16 weeks of active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV: 24-week treatment
Description: 24 weeks of active treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127: 16-week treatment
Description: 16 weeks of active treatment
Study: NCT02732990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)
Study: NCT00857766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS™ 250/50mcg
Description: ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: COPD subjects-Placebo DISKUS
Study: NCT00826826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: (Pulmonary vein isolation)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Catheter ablation
Description: (Pulmonary vein isolation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: From the day of the catheter ablation procedure and 8 weeks forward.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From the day of the catheter ablation procedure and 8 weeks forward.
Study: NCT03080805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Plus Capecitabine
Description: pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/ m\^2 BID)
Study: NCT04023357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK
Description: New polyetheretherketones material

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emax
Description: standard etchable glass ceramic used for Endocrowns
Study: NCT01134328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC-150B 0.005%
Description: 1 drop in each eye once per day for up to 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Vehicle
Description: 1 drop in each eye once per day for up to 14 days
Study: NCT02558972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Northera (Droxidopa)
Description: Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
Study: NCT04216368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balance training
Description: The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: resistance training
Description: Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resistance training
Description: Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
Study: NCT03080805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib Plus Capecitabine
Description: Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
Study: NCT00647400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg every other week, subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 80 mg every other week, subcutaneous
Study: NCT03044457

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKA
Description: femoral and tibial positioning using the reversed gap technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKA
Description: femoral and tibial positioning using the reversed gap technique
Study: NCT03510416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib is a kind of Inhibitor of VEGFR-2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TACE
Description: Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
Study: NCT03578965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: -If patient has a penicillin allergy then clindamycin will be used. Prophylactic antibiotics should be administered prior to skin incision
Study: NCT01279707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanised monoclonal antibody, veltuzumab
Description: Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanised monoclonal antibody epratuzumab
Description: Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanised monoclonal antibodies veltuzumab and epratuzumab
Description: Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
Study: NCT02206815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor+Warfarin
Description: Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel+Aspirin+Warfarin
Description: Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
Study: NCT02040870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: 750 mg once daily
Study: NCT04347941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone Positioning
Description: Patient will be asked to remain for at least one hour and to a maximum total of 16 hours in prone position with 45 minutes breaks for meals. Immediately prior to proning, if spO2 \<94% on FiO2 0.4, start on 100% O2 to ensure stability during proning. A nurse or assistant will assist patient to turn on side and then face down with the support of pillows as required for comfort, ensure that they are predominantly on their chest rather than on their side. Arms can be at side, in swimmer position and can be moved to patients' comfort, pillows under knees and chest for comfort and call bell to be at patient's arm's length. Vitals and work of breathing score will be measured before and at 1 hour into each proning session and at the end of each session. Total length of time in prone position will be recorded. Intervention to continue daily until oxygen requirement to maintain spO2 \>94% is below FiO2 0.4 via venturi facemask or high flow nasal cannula

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care.
Description: Standard of care. Prone positioning may be administered as a rescue therapy